Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.
The human antibody response to influenza virus infection plays a protective role against re-infection, yet little molecular detail is available regarding how human antibodies, when characterized at the monoclonal level, neutralize this important human pathogen. Recent studies, using a diverse array of strategies, have isolated and characterized human anti-virus neutralizing antibodies and shed light not only on the specificity and origin of these antibodies but on their potential for therapeutic use against influenza virus infection.
Martinez
Osvaldo
O
Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA. osvaldo.martinez@mssm.edu
Tsibane
Tshidi
T
Basler
Christopher F
CF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory; D007252:Influenza Vaccines / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D009500:Neutralization Tests; D009975:Orthomyxoviridae / Q000276:immunology*; D019151:Peptide Library
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D019151:Peptide Library